Free Trial
NASDAQ:ATXS

Astria Therapeutics Q3 2025 Earnings Report

Astria Therapeutics EPS Results

Actual EPS
-$0.55
Consensus EPS
-$0.41
Beat/Miss
Missed by -$0.14
One Year Ago EPS
N/A

Astria Therapeutics Revenue Results

Actual Revenue
$0.71 million
Expected Revenue
$10.67 million
Beat/Miss
Missed by -$9.96 million
YoY Revenue Growth
N/A

Astria Therapeutics Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call Date
Wednesday, November 12, 2025
Conference Call Time
8:00AM ET

Astria Therapeutics Earnings Headlines

Astria Stockholders Vote to Approve Acquisition by BioCryst
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners guide...please take a few seconds and download it right now before your download link expires. That way, no matter what it costs in the future, you'll have a free copy on your computer.tc pixel
See More Astria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Astria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Astria Therapeutics and other key companies, straight to your email.

About Astria Therapeutics

Astria Therapeutics (NASDAQ:ATXS) is a clinical‐stage biotechnology company dedicated to the development of innovative immunotherapies for oncology and autoimmune diseases. The company leverages proprietary cell engineering platforms to create next‐generation agents that engage T cells and natural killer (NK) cells, with the goal of directing potent and specific immune responses against tumor‐associated antigens or diseased tissues.

Astria’s pipeline encompasses multiple therapeutic candidates across both hematologic and solid tumor indications, as well as autoimmune disorders. Its lead clinical programs are designed to harness bispecific constructs and cell‐based activation technologies to improve the precision and durability of immune killing, while additional preclinical assets focus on expanding the scope of treatable targets and refining safety profiles.

Founded in 2018 and headquartered in San Diego, California, Astria Therapeutics collaborates with academic institutions, contract research organizations and regulatory authorities throughout North America and Europe to advance its product candidates. The company is guided by an executive team with extensive biopharmaceutical industry experience and a board of directors that brings together scientific, clinical and commercial expertise to support its strategic development plan.

View Astria Therapeutics Profile